Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04554459 | Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL(Pona-CELL) | terminated | Phase 2 | 4 | Institute of Hematology and Blood Transfusion, Czech RepublicOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT04676087 | Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides | terminated | Phase 1 / Phase 2 | 5 | Emory UniversityOTHER | 1 |
| Aug 13, 2024 |
| clinicaltrials |
| NCT02091063 | ACY-1215 for Relapsed/Refractory Lymphoid Malignancies | terminated | Phase 1 / Phase 2 | 23 | Jennifer AmengualOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT00522990 | Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias | terminated | Phase 1 / Phase 2 | 48 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT00848601 | Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma | terminated | Phase 1 | 14 | Astex Pharmaceuticals, Inc.INDUSTRY | 2 | Aug 2, 2024 | clinicaltrials |
| NCT04852822 | Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | — | 350 | University of WashingtonOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT04545333 | The clonoSEQ® Watch Registry | terminated | — | 465 | Adaptive BiotechnologiesINDUSTRY | 1 | Aug 1, 2024 | clinicaltrials |
| NCT05908396 | Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma | terminated | Phase 1 | 4 | IGM Biosciences, Inc.INDUSTRY | 1 | Aug 1, 2024 | clinicaltrials |
| NCT04806035 | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia | terminated | Phase 1 | 21 | TG Therapeutics, Inc.INDUSTRY | 1 | Jul 31, 2024 | clinicaltrials |
| NCT03435250 | Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss | terminated | Phase 1 | 123 | Institut de Recherches Internationales ServierOTHER | 3 | Jul 25, 2024 | clinicaltrials |
| NCT04082936 | A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 97 | IGM Biosciences, Inc.INDUSTRY | 7 | Jul 24, 2024 | clinicaltrials |
| NCT05360238 | Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL | terminated | Phase 1 / Phase 2 | 20 | Mustang BioINDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT05645744 | Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. | terminated | — | 3 | Mustang BioINDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT03671590 | Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies | terminated | Phase 1 | 172 | TG Therapeutics, Inc.INDUSTRY | 2 | Jul 19, 2024 | clinicaltrials |
| NCT03198234 | Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders(T-allo10) | terminated | Phase 1 | 5 | Roncarolo, Maria Grazia, MDOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT05272813 | A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL | terminated | Phase 1 / Phase 2 | 13 | Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT05720052 | A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma | terminated | Phase 1 / Phase 2 | 8 | MingSight Pharmaceuticals, IncINDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT04072393 | Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers | terminated | N/A | 24 | Washington University School of MedicineOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT02110563 | Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma | terminated | Phase 1 | 50 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyINDUSTRY | 1 | Jul 11, 2024 | clinicaltrials |
| NCT00838955 | Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma | terminated | Phase 2 | 14 | Loyola UniversityOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT03088709 | Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide | terminated | Phase 2 | 5 | Loyola UniversityOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT02400242 | Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma | terminated | Phase 1 | 85 | CelgeneINDUSTRY | 5 | Jul 9, 2024 | clinicaltrials |
| NCT04933617 | Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas | terminated | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | Jul 9, 2024 | clinicaltrials |
| NCT02295722 | GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma(GEMHDM2014) | terminated | Phase 1 / Phase 2 | 100 | AHS Cancer Control AlbertaOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT05105412 | Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas | terminated | Phase 1 / Phase 2 | 12 | National Health Research Institutes, TaiwanOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT02742090 | Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy | terminated | Phase 2 | 51 | TG Therapeutics, Inc.INDUSTRY | 1 | Jul 3, 2024 | clinicaltrials |
| NCT02863991 | Oral ONC201 in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 17 | Jazz PharmaceuticalsINDUSTRY | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03777410 | Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma | terminated | — | 33 | Travera IncINDUSTRY | 1 | Jul 3, 2024 | clinicaltrials |
| NCT04111107 | Precision Medicine for Patients With Identified Actionable Mutations | terminated | Phase 2 | 45 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03448978 | Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma | terminated | Phase 1 | 32 | Cartesian TherapeuticsINDUSTRY | 1 | Jul 1, 2024 | clinicaltrials |
| NCT04352205 | Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure | terminated | Phase 2 | 17 | Emory UniversityOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT05000450 | Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 6 | Allogene TherapeuticsINDUSTRY | 1 | Jun 28, 2024 | clinicaltrials |
| NCT03451825 | Phase I/II Study of Avelumab in Pediatric Cancer Participants | terminated | Phase 1 | 21 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 5 | Jun 24, 2024 | clinicaltrials |
| NCT01670994 | QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 6 | Altor BioScienceINDUSTRY | 1 | Jun 18, 2024 | clinicaltrials |
| NCT04074330 | A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 38 | TakedaINDUSTRY | 9 | Jun 14, 2024 | clinicaltrials |
| NCT04956302 | Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 1 | Abdullah KhanOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT05048732 | Imaging Apoptosis for Lymphoma Treatment Response | terminated | Early Phase 1 | 12 | Washington University School of MedicineOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT03789864 | Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides(BDI) | terminated | N/A | 1 | Indiana UniversityOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT00346632 | An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia | terminated | Phase 1 | 37 | Kyowa Kirin, Inc.INDUSTRY | 1 | May 17, 2024 | clinicaltrials |
| NCT04722601 | A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma | terminated | Phase 1 / Phase 2 | 2 | University of ChicagoOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT04718610 | Heart Rate Variability, Vagus Nerve and Cancer | terminated | N/A | 25 | Centre Hospitalier Henri Duffaut - AvignonOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT05022797 | Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS | terminated | Phase 2 | 3 | Fundacion CRIS de Investigación para Vencer el CáncerOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT02624388 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)(UVA-Gen001) | terminated | Phase 2 | 4 | University of VirginiaOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT03225716 | A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia | terminated | Phase 1 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT04167137 | Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants | terminated | Phase 1 | 32 | SynlogicINDUSTRY | 1 | May 3, 2024 | clinicaltrials |
| NCT05410574 | Family-Based Behavioral Treatment for Childhood Survivors of Acute Lymphoblastic Leukemia | terminated | N/A | 17 | Washington University School of MedicineOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT04407442 | Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab | terminated | Phase 2 | 5 | University of California, San FranciscoOTHER | 1 | Apr 30, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Aug 14, 2024source: clinicaltrials